Open AccessAdjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Author(s) -
Gary M. Strauss,
James E. Herndon,
Michael A. Maddaus,
David W. Johnstone,
Elizabeth A. Johnson,
David H. Harpole,
Heidi H. Gillenwater,
Dorothy Watson,
David J. Sugarbaker,
Richard L. Schilsky,
Everett E. Vokes,
Mark R. Green
Publication year - 2008
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2008.16.4855
Subject(s) - medicine , carboplatin , lung cancer , oncology , paclitaxel , radiation therapy , adjuvant , cancer , leukemia , chemotherapy , cisplatin
Adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival. Although there is strong evidence that adjuvant chemotherapy is effective in stages II and IIIA NSCLC, its utility in stage IB disease is unclear. This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom